Carfilzomib is a novel, highly selective tetrapeptide epoxyketone proteasome inhibitor for use in patients with multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in individuals 12 years and older, who have been symptomatic for less than 24 hours.
On November 16, the 3rd Sustained Release Drug R&D International Summit and 2019 APIs Industrial Park (Changsha) Investment Cooperation Forum ended successfully in Changsha. The forum was hosted by the People's Government of Wangcheng District of Changsha City and the Promotion Office of Biomedical Industry Chain of Changsha City, and undertaken by Hunan Huateng Pharmaceutical Co., Ltd..
We are honored to invite you to attend the 3rd Sustained-Release Drug R&D International Summit to be held at Preess Resort & Hotel, Wangcheng, Changsha, Hunan, China, on November 14-16, 2019, which is organized by the People's Government of Wangcheng District, Changsha.
Huateng Pharmac raised 50 million yuan in the series A round of funding led by Tianshili Capital's Boyi Fund and followed by Zhuhai Danchi Equity Investment Fund, and Hunan Dingteng Juzhi Investment Partnership.
Copyright © 2013-2019 Hunan HuaTeng Pharmaceutical Co., Ltd. All right reserved Tel: +86-0731-82251112 ex 814 / 815, +1 857-928-2050 E-mail: email@example.com
Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China. ZIP Code: 410006